Table 4.
Univariate analysis of overall survival (OS) from the initiation of AMR therapy
| Overall survival (OS) | |||
|---|---|---|---|
| Variables | Hazard ratio | 95% CI | P‐value |
| Age (≤ 66 vs. ≥ 67 years) | 1.58 | 0.87–3.08 | 0.13 |
| Gender (male vs. female) | 1.24 | 0.64–2.37 | 0.53 |
| PS (0 vs.1,2) | 0.37 | 0.15–0.58 | <0.01 |
| Stage (IIIA, IIIB vs. IV) | 0.22 | 0.15–0.57 | <0.01 |
| EGFR mutation status (mutation vs. wild‐type, unknown) | 0.99 | 0.46–2.13 | 0.97 |
| Histology (adenocarcinoma vs. nonadenocarcinoma) | 1.10 | 0.56–2.13 | 0.79 |
| Smoking status (smoker vs. non‐smoker) | 1.25 | 0.66–2.36 | 0.51 |
| Number of regimens before AMR (<3 vs. ≥ 3) | 0.59 | 0.31–1.08 | 0.09 |
| Response to AMR (PR vs. SD, PD) | 0.43 | 0.23–1.25 | 0.15 |
| topoisomerase‐II (low vs. high) | 0.47 | 0.16–0.84 | 0.02 |
| Ki‐67 labeling index (<20 LI vs. ≥20 LI) | 1.09 | 0.59–2.02 | 0.79 |
AMR, amrubicin; CI, confidence interval; CR, complete response; EGFR, epidermal growth factor receptor; HR, hazard ratio; LI, labeling index; OS, overall survival; PD, progressive disease; PR, partial response; PS, performance status; SD, stable disease.